Department of Radiation Oncology, Qianfoshan hospital affiliated to Shandong University, 16766 Jingshi Road, Jinan, 250014, P.R. China.
Division of Oncology, Department of Graduate, Weifang Medical College, 7166 Baotongxi Road, Weifang, 261053, P.R. China.
Sci Rep. 2017 Feb 17;7:42913. doi: 10.1038/srep42913.
The outcomes of studies analyzing the prognostic role of CTLA-4 in cancers are controversial. Therefore, the aim of our meta-analysis was to clarify the correlation between CTLA-4 expression and OS in different cancer cases. Relevant literature was searched using PubMed, EMBASE, Web of Science, and the Cochrane Library. The clinicopathological features, hazard ratio (HR) and 95% confidence intervals (CI) were collected from these studies and were analyzed using Stata version 12.0 software. The pooled HR values showed no significant correlation between CTLA-4 expression levels and OS in relation to tumors (HR: 1.24, 95% CI: 0.98-1.56, I2 = 71.7%, P = 0.000). Further subgroup analyses were conducted and categorized by experimental methods, CTLA-4 sources and cancer types. The survey showed a significant correlation (HR: 1.47, 95% CI: 1.14-1.89) between high expression of CTLA-4 and OS in the SNP subgroup, and subgroups analyzing by PCR (HR: 1.50, 95% CI: 1.20-1.86) and flow cytometry (HR: 2.76, 95% CI: 1.49-5.14). In addition, our analysis observed significant differences between patients and controls in inCTLA-4+CD4+ lymphocytes, surCTLA-4+CD4+ lymphocytes, inCTLA-4+CD8+ lymphocytes, and surCTLA-4+CD8+ lymphocytes. Knowledge of the effects of CTLA-4 could potentially be used to effectively guide appropriate prognosis and therapeutic strategies in cancer patients.
CTLA-4 在癌症中的预后作用的研究结果存在争议。因此,我们的荟萃分析旨在阐明 CTLA-4 表达与不同癌症病例的 OS 之间的相关性。使用 PubMed、EMBASE、Web of Science 和 Cochrane Library 搜索相关文献。从这些研究中收集临床病理特征、风险比 (HR) 和 95%置信区间 (CI),并使用 Stata 版本 12.0 软件进行分析。合并的 HR 值表明 CTLA-4 表达水平与 OS 之间没有显著相关性(HR:1.24,95%CI:0.98-1.56,I2=71.7%,P=0.000)。进一步进行了亚组分析,并按实验方法、CTLA-4 来源和癌症类型进行分类。调查显示,SNP 亚组中 CTLA-4 高表达与 OS 之间存在显著相关性(HR:1.47,95%CI:1.14-1.89),PCR 亚组(HR:1.50,95%CI:1.20-1.86)和流式细胞术亚组(HR:2.76,95%CI:1.49-5.14)。此外,我们的分析还观察到 inCTLA-4+CD4+淋巴细胞、surCTLA-4+CD4+淋巴细胞、inCTLA-4+CD8+淋巴细胞和 surCTLA-4+CD8+淋巴细胞在患者和对照组之间存在显著差异。了解 CTLA-4 的作用可能有助于有效指导癌症患者的适当预后和治疗策略。